Clinical trials of biologic modifiers that block immunoglobulin (Ig) E, IL-5 or IL-4 receptor alpha (IL-4R alpha) subunit have demonstrated efficacy and safety in treating patients with uncontrolled severe asthma [16,17,18,19,20]. The gene discussed is IL5; the disease is asthma.